Clinical
|
Age, years
|
57 ± 16
|
Male
|
140 (56)
|
Smoking status
|
Smoker (NA = 3)
|
98 (40)
|
Number of pack-years
|
21 ± 18
|
Comorbidities
|
Immunocompromised
|
163 (65)
|
Solid cancer
|
65 (26)
|
Hematological cancer
|
56 (22)
|
Solid organ transplant
|
39 (16)
|
Bone marrow transplant
|
24 (10)
|
Connective tissue diseases
|
20 (8)
|
HIV positive
|
8 (3)
|
Treatments
|
Corticosteroid
|
75 (30)
|
Dose, mg/day
|
16.5 ± 16
|
Methotrexate
|
18 (7)
|
Mycophenolate mofetil
|
20 (8)
|
Ciclosporin
|
20 (8)
|
Chemotherapy
|
29 (12)
|
Immunotherapy
|
11 (4)
|
Pneumocystis prophylaxis
|
43 (17)
|
Radiological
|
Lesions on chest CT scan (NA = 21)
|
Ground glass opacities
|
179 (79)
|
Reticulation
|
88 (39)
|
Micronodules
|
66 (29)
|
Consolidation
|
62 (27)
|
Septa thickening
|
37 (16)
|
Mosaic attenuation
|
11 (5)
|
Bilateral lesions
|
197 (86)
|
Distribution (NA = 21)
|
Diffuse
|
136 (60)
|
Lower lobes
|
54 (24)
|
Upper lobes
|
32 (14)
|
Biological
|
Serum biology
|
Leukocytes, giga/L (NA = 36)
|
8.0 ± 6.0
|
Neutrophils, giga/L (NA = 47)
|
5.5 ± 4.0
|
Lymphocytes, giga/L (NA = 47)
|
1.6 ± 3.7
|
Eosinophils, giga/L (NA = 48)
|
0.18 ± 0.21
|
Hemoglobin, g/dL (NA = 36)
|
12.1 ± 2.2
|
Platelets, giga/L (NA = 39)
|
278 ± 561
|
CRP, mg/dL (NA = 92)
|
65.4 ± 73.2
|
Bronchial fibroscopy
|
Bacteria
|
37 (15)
|
Mycobacteria (NA = 4)
|
7 (3)
|
Positive viral PCR (NA = 18)
|
34 (15)
|
Fungi
|
94 (38)
|
Pneumocystis cysts (direct examination)
|
17 (7)
|
Positive Pneumocystis PCR (NA = 75)
|
89 (51)
|
Pneumocystis PCR copies (NA = 4)
|
Colonization
|
32 (38)
|
Intermediate
|
25 (29)
|
Infection
|
28 (33)
|
BAL cellularity, cells/ml
|
245,692 ± 350,317
|
Cell populations on BAL, % (NA = 4)
|
Macrophages
|
43 ± 17
|
Lymphocytes
|
51 ± 18
|
Neutrophils
|
5 ± 8
|
Eosinophils
|
1.5 ± 4
|
Morphological abnormalities on BAL, (NA = 1)
|
Activated lymphocytes
|
238 (96)
|
Macrophages into cohesive clusters
|
245 (99)
|
Epithelioid transformation of macrophages
|
240 (97)
|
Foamy macrophages
|
185 (75)
|